Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 116

1.

Vandetanib: opening a new treatment practice in advanced medullary thyroid carcinoma.

Durante C, Paciaroni A, Plasmati K, Trulli F, Filetti S.

Endocrine. 2013 Oct;44(2):334-42. doi: 10.1007/s12020-013-9943-9. Epub 2013 Apr 14. Review.

PMID:
23584948
2.

Vandetanib and the management of advanced medullary thyroid cancer.

Campbell MJ, Seib CD, Gosnell J.

Curr Opin Oncol. 2013 Jan;25(1):39-43. doi: 10.1097/CCO.0b013e32835a42b9. Review.

PMID:
23202050
3.

Vandetanib for the treatment of medullary thyroid cancer.

Chau NG, Haddad RI.

Clin Cancer Res. 2013 Feb 1;19(3):524-9. doi: 10.1158/1078-0432.CCR-12-2353. Epub 2012 Dec 11. Review.

4.

Vandetanib therapy in medullary thyroid cancer.

Grabowski P, Briest F, Baum RP, Zaknun JJ, Kulkarni HR, Zeitz M, Hörsch D.

Drugs Today (Barc). 2012 Nov;48(11):723-33. doi: 10.1358/dot.2012.48.11.1867323. Review.

PMID:
23170308
5.

Vandetanib: a novel targeted therapy for the treatment of metastatic or locally advanced medullary thyroid cancer.

Ton GN, Banaszynski ME, Kolesar JM.

Am J Health Syst Pharm. 2013 May 15;70(10):849-55. doi: 10.2146/ajhp120253. Review.

PMID:
23640345
6.

Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial.

Leboulleux S, Bastholt L, Krause T, de la Fouchardiere C, Tennvall J, Awada A, Gómez JM, Bonichon F, Leenhardt L, Soufflet C, Licour M, Schlumberger MJ.

Lancet Oncol. 2012 Sep;13(9):897-905. doi: 10.1016/S1470-2045(12)70335-2. Epub 2012 Aug 14.

PMID:
22898678
7.

[Vandetanib, in the management of patients with locally advanced or metastatic medullary thyroid carcinomas].

Chougnet CN, Schlumberger M, Leboulleux S, Baudin E.

Bull Cancer. 2014 Sep;101(9):891-5. doi: 10.1684/bdc.2014.2022. Review. French.

PMID:
25296193
8.

Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer.

Wells SA Jr, Gosnell JE, Gagel RF, Moley J, Pfister D, Sosa JA, Skinner M, Krebs A, Vasselli J, Schlumberger M.

J Clin Oncol. 2010 Feb 10;28(5):767-72. doi: 10.1200/JCO.2009.23.6604. Epub 2010 Jan 11.

9.

Vandetanib for the treatment of medullary thyroid carcinoma.

Cooper MR, Yi SY, Alghamdi W, Shaheen DJ, Steinberg M.

Ann Pharmacother. 2014 Mar;48(3):387-94. doi: 10.1177/1060028013512791. Epub 2013 Nov 14. Review.

PMID:
24259657
10.

Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer.

Robinson BG, Paz-Ares L, Krebs A, Vasselli J, Haddad R.

J Clin Endocrinol Metab. 2010 Jun;95(6):2664-71. doi: 10.1210/jc.2009-2461. Epub 2010 Apr 6.

11.

Vandetanib: in medullary thyroid cancer.

Frampton JE.

Drugs. 2012 Jul 9;72(10):1423-36. doi: 10.2165/11209300-000000000-00000. Review.

PMID:
22715896
12.

Selective use of vandetanib in the treatment of thyroid cancer.

Fallahi P, Di Bari F, Ferrari SM, Spisni R, Materazzi G, Miccoli P, Benvenga S, Antonelli A.

Drug Des Devel Ther. 2015 Jul 3;9:3459-70. doi: 10.2147/DDDT.S72495. eCollection 2015. Review.

13.

Vandetanib for the treatment of advanced medullary thyroid cancer outside a clinical trial: results from a French cohort.

Chougnet CN, Borget I, Leboulleux S, de la Fouchardiere C, Bonichon F, Criniere L, Niccoli P, Bardet S, Schneegans O, Zanetta S, Schvartz C, Drui D, Chauffert B, Rohmer V, Schlumberger M.

Thyroid. 2015 Apr;25(4):386-91. doi: 10.1089/thy.2014.0361. Epub 2015 Feb 18.

PMID:
25627619
14.

Vandetanib for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease: U.S. Food and Drug Administration drug approval summary.

Thornton K, Kim G, Maher VE, Chattopadhyay S, Tang S, Moon YJ, Song P, Marathe A, Balakrishnan S, Zhu H, Garnett C, Liu Q, Booth B, Gehrke B, Dorsam R, Verbois L, Ghosh D, Wilson W, Duan J, Sarker H, Miksinski SP, Skarupa L, Ibrahim A, Justice R, Murgo A, Pazdur R.

Clin Cancer Res. 2012 Jul 15;18(14):3722-30. doi: 10.1158/1078-0432.CCR-12-0411. Epub 2012 Jun 4.

15.

Vandetanib for the treatment of thyroid cancer.

Langmuir PB, Yver A.

Clin Pharmacol Ther. 2012 Jan;91(1):71-80. doi: 10.1038/clpt.2011.272. Epub 2011 Dec 7. Review.

PMID:
22158569
16.

The discovery and development of vandetanib for the treatment of thyroid cancer.

Sim MW, Cohen MS.

Expert Opin Drug Discov. 2014 Jan;9(1):105-14. doi: 10.1517/17460441.2014.866942. Epub 2013 Dec 4. Review.

PMID:
24299515
17.

Vandetanib: first global approval.

Commander H, Whiteside G, Perry C.

Drugs. 2011 Jul 9;71(10):1355-65. doi: 10.2165/11595310-000000000-00000.

PMID:
21770481
18.

Mitochondria-targeted nitroxide, Mito-CP, suppresses medullary thyroid carcinoma cell survival in vitro and in vivo.

Starenki D, Park JI.

J Clin Endocrinol Metab. 2013 Apr;98(4):1529-40. doi: 10.1210/jc.2012-3671. Epub 2013 Mar 18.

19.

Vandetanib for the treatment of thyroid cancer: an update.

Karras S, Anagnostis P, Krassas GE.

Expert Opin Drug Metab Toxicol. 2014 Mar;10(3):469-81. doi: 10.1517/17425255.2014.885015. Epub 2014 Feb 6. Review.

PMID:
24502390
20.

Vandetanib: too dangerous in medullary thyroid cancer.

[No authors listed]

Prescrire Int. 2012 Oct;21(131):233.

PMID:
23185843
Items per page

Supplemental Content

Write to the Help Desk